Rate Video

ESMO Sarcoma & GIST 2022 | The advantages of face-to-face meetings

Robin Jones • 9 Feb 2022

ESMO Sarcoma & GIST 2022

Gastrointestinal Cancer Sarcoma

Robin Jones, MBBS, MRCP, MD, talks on the advantages of face-to-face meetings as opposed to virtual. This interview took place during the European Society for Medical Oncology (ESMO) Sarcoma & GIST Symposium.

DeFi trial: nirogacestat vs placebo for patients with progressing desmoid tumors

Robin Jones • 1 Nov 2022

The significance of interactive and educational meetings for sarcoma

Robin Jones • 9 Feb 2022

P10015/SARC033: trametinib in advanced EHE

Robin Jones • 15 Jun 2021

Highlights from ESMO Sarcoma & GIST 2022

Robin Jones • 9 Feb 2022

Related Videos

EuropaColon survey of the unmet needs of metastatic colorectal cancer patients

Geoffrey Henning

Hitting back at HCC: future landscape of treatment

Jean Frédéric Blanc

Pancreatic cancer: moving forward

Key outcomes of the Phase 1b of atezolizumab and bevacizumab for advanced HCC

Michael Pishvaian